Myelofibrosis

• A study of pelabresib and ruxolitinib compared to placebo and ruxolitinib in adult patients with myelofibrosis who have not received prior t … Pending
  2025-523555-66-00 5
• A Phase 1 Study of AJ1-11095 in Adults with Myelofibrosis Failed by a JAK2 Inhibitor Recruiting
  2025-522033-64-00 1 2026-02-26
• RVU120 Rollover Study Recruiting
  2025-521673-14-00 4 2025-12-03 "Relapsed / Refractory Metastatic or Advanced Solid Tumors"
• A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms Recruiting
  2023-506145-38-00 3 2021-05-11 "Treatment of participants with MF, MDS, ET, or MDS/MPN"
• Pacritinib for Patients With Myelofibrosis Who Have Thrombocytopenia Recruiting
  2025-522509-39-00 4 2026-03-30 "Patients with myelofibrosis and platelets counts between 50 "
• Ruxolitinib rollover study Recruiting
  2023-507225-42-00 4 2024-11-05
• Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis Recruiting
  2023-504724-25-00 5 2024-10-16 "Primary Myelofibrosis"
• A Phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects with JAK inhibitor-naïve myelofibrosis and moderate … Recruiting
  2024-511309-47-00 4 2024-07-17 "moderate thrombocytopenia"
• A clinical study of bomedemstat for people in a prior bomedemstat study Recruiting
  2023-506996-89-00 5 2024-06-13 "Myeloproliferative Neoplasms (Essential Thrombocythemia, Pol"
• Phase 1/2 Study of Oral Nuvisertib (TP-3654) in Patients with Myelofibrosis Recruiting
  2022-502597-16-00 9 2023-10-27 "Intermediate or High-risk Primary or Secondary Myelofibrosis"
• A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB … Recruitment ended
  2023-506139-13-00 5 2024-01-04 "Treatment naïve patients with MF"
• A study to evaluate KER-050 as a monotherapy or in combination with Ruxolitinib in Myelofibrosis. Recruitment ended
  2023-507468-38-00 4 2022-04-22
• A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants with Previously Treated Myelofibrosis Recruitment ended
  2024-513605-31-00 4 2021-10-21
• A Phase 1b/2 Study of BMS-986158 Monotherapy and Combination with either Ruxolitinib or Fedratinib in Intermediate or High Risk Myelofibrosi … Recruitment ended
  2023-509635-89-00 9 2021-06-01 "DIPSS-Intermediate or High Risk Myelofibrosis"
• A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Alone and in Combination With Ruxolitinib in Participants Wit … Recruitment ended
  2023-507274-40-00 3 2021-04-22
• A study comparing current available therapies with imetelstat for the treatment of intermediate-2 or high-risk MF who are not responding to … Recruitment ended
  2023-509120-17-00 5 2021-04-12
• A study to evaluate the benefit and safety of Luspatercept (ACE-536) in adults with myeloproliferative neoplasm-associated myelofibrosis on … Recruitment ended
  2023-507890-17-00 5 2021-02-22 "Anemia associated with myeloproliferative neoplasm (MPN)-ass"
• A phase 3B, open-label, single-arm, rollover study to evaluate long-term safety of Luspatercept in subjects who have participated in other L … Recruitment ended
  2022-502498-40-00 5 2019-07-26 "myelodysplastic syndrome (MDS); beta (β)-thalassemia (THAL);"
• Extended Access of Momelotinib for Subjects with Myelofibrosis Recruitment ended
  2023-508018-41-00 4 2018-07-27 "Primary Myelofibrosis (PMF), Post-polycythemia Vera or Post-"
• INCB 39110-801 A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Stu … Ended
  2022-501661-47-00 4 2023-08-23 "Myelofibrosis ; postlung transplant (BOS); chronic graft-ver"
• Study to evaluate the efficacy and safety of fedratinib in combination with CC-486 in patients suffering from myelofibrosis in acute phase. Ended
  2024-519227-22-00 9 2022-11-03 "Myeloproliferative neoplasm in accelerated phase (MPN-AP)"
• A study comparing current standard therapies with fedratinib for the treatment of myelofibrosis (either diagnosed alone or after polycythemi … Ended
  2024-511972-33-00 5 2019-08-05 "Primary myelofibrosis, post-polycythemia vera myelofibrosis "

Showing 1–22 of 22 trials